Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Allergan |
---|---|
Information provided by: | Allergan |
ClinicalTrials.gov Identifier: | NCT00533351 |
This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia
Condition | Intervention | Phase |
---|---|---|
Neuralgia |
Drug: AGN 201781 Drug: placebo capsule |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Crossover Assignment, Safety/Efficacy Study |
Enrollment: | 9 |
Study Start Date: | March 2008 |
Study Completion Date: | June 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
50 mg
|
Drug: AGN 201781
50 mg capsules three-times daily for 2 weeks
|
2: Placebo Comparator
Placebo capsule
|
Drug: placebo capsule
50 mg capsules three-times daily for 2 weeks
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Allergan, Inc. ( Therapeutic Area Head ) |
Study ID Numbers: | 201781-504 |
Study First Received: | September 19, 2007 |
Last Updated: | October 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00533351 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Australia: Therapeutic Goods Agency |
Signs and Symptoms Neuromuscular Diseases Neuralgia |
Peripheral Nervous System Diseases Neurologic Manifestations Pain |
Signs and Symptoms Neuromuscular Diseases Neuralgia Peripheral Nervous System Diseases |
Nervous System Diseases Neurologic Manifestations Pain |